* inability to provide informed consent * patients expected to survive less than 24 hours * advanced directives of patient's wishes to refuse intubation. * patients on mechanical ventilation * pregnant women \[pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hcg) laboratory test\] * breastfeeding * weight \> 100 kg or \< 50 kg * cancer not in remission or active serious illness unrelated to covid-19. * any of the following laboratory results at screening: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) \< 50 g /l, alanine transaminase (alt) or aspartate transaminase (ast) \> 5n, egfr \< 30 ml/min * current documented bacterial infection * known infection with human immunodeficiency virus, treponema pallidum, hepatitis b antigen (serology consistent with previous vaccination and a history of vaccination is acceptable) or hepatitis c * on-going therapy against tuberculosis, or exposed to tuberculosis or have travelled in areas with high risk of tuberculosis or mycosis within the last 3 months * known allergies to a component of the protrans® product * pre-existing chronic respiratory diseases requiring long-term oxygen therapy or severe pulmonary hypertension (paps \>30 mm hg) or pulmonary fibrosis * pre-existing cirrhosis with basal child and pugh of c

* inability to provide informed consent * patients expected to survive less than 24 hours * advanced directives of patient's wishes to refuse intubation. * patients on mechanical ventilation * pregnant women \[pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hcg) laboratory test\] * breastfeeding * weight \> 100 kg or \< 50 kg * cancer not in remission or active serious illness unrelated to covid-19. * any of the following laboratory results at screening: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) \< 50 g /l, alanine transaminase (alt) or aspartate transaminase (ast) \> 5n, egfr \< 30 ml/min * current documented bacterial infection * known infection with human immunodeficiency virus, treponema pallidum, hepatitis b antigen (serology consistent with previous vaccination and a history of vaccination is acceptable) or hepatitis c * on-going therapy against tuberculosis, or exposed to tuberculosis or have travelled in areas with high risk of tuberculosis or mycosis within the last 3 months * known allergies to a component of the protrans® product * pre-existing chronic respiratory diseases requiring long-term oxygen therapy or severe pulmonary hypertension (paps \>30 mm hg) or pulmonary fibrosis * pre-existing cirrhosis with basal child and pugh of c

- inability to provide informed consent - patients expected to survive less than 24 hours - advanced directives of patient's wishes to refuse intubation. - patients on mechanical ventilation - pregnant women [pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hcg) laboratory test] - breastfeeding - weight > 100 kg or < 50 kg - cancer not in remission or active serious illness unrelated to covid-19. - any of the following laboratory results at screening: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) < 50 g /l, alanine transaminase (alt) or aspartate transaminase (ast) > 5n, egfr < 30 ml/min - current documented bacterial infection - known infection with human immunodeficiency virus, treponema pallidum, hepatitis b antigen (serology consistent with previous vaccination and a history of vaccination is acceptable) or hepatitis c - on-going therapy against tuberculosis, or exposed to tuberculosis or have travelled in areas with high risk of tuberculosis or mycosis within the last 3 months - known allergies to a component of the protrans® product - pre-existing chronic respiratory diseases requiring long-term oxygen therapy or severe pulmonary hypertension (paps >30 mm hg) or pulmonary fibrosis - pre-existing cirrhosis with basal child and pugh of c

- inability to provide informed consent - patients expected to survive less than 24 hours - advanced directives of patient's wishes to refuse intubation. - patients on mechanical ventilation - pregnant women [pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hcg) laboratory test] - breastfeeding - weight > 100 kg or < 50 kg - cancer not in remission or active serious illness unrelated to covid-19. - any of the following laboratory results at screening: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) < 50 g /l, alanine transaminase (alt) or aspartate transaminase (ast) > 5n, egfr < 30 ml/min - current documented bacterial infection - known infection with human immunodeficiency virus, treponema pallidum, hepatitis b antigen (serology consistent with previous vaccination and a history of vaccination is acceptable) or hepatitis c - on-going therapy against tuberculosis, or exposed to tuberculosis or have travelled in areas with high risk of tuberculosis or mycosis within the last 3 months - known allergies to a component of the protrans® product - pre-existing chronic respiratory diseases requiring long-term oxygen therapy or severe pulmonary hypertension (paps >30 mm hg) or pulmonary fibrosis - pre-existing cirrhosis with basal child and pugh of c